[go: up one dir, main page]

DE69912304D1 - Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen - Google Patents

Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen

Info

Publication number
DE69912304D1
DE69912304D1 DE69912304T DE69912304T DE69912304D1 DE 69912304 D1 DE69912304 D1 DE 69912304D1 DE 69912304 T DE69912304 T DE 69912304T DE 69912304 T DE69912304 T DE 69912304T DE 69912304 D1 DE69912304 D1 DE 69912304D1
Authority
DE
Germany
Prior art keywords
occular
treatment
neovascular diseases
staurosporine derivatives
staurosporine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69912304T
Other languages
English (en)
Other versions
DE69912304T2 (de
Inventor
Kimbro Brazzell
Marjorie Wood
Anthony Campochiaro
Elizabeth Kane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE69912304D1 publication Critical patent/DE69912304D1/de
Publication of DE69912304T2 publication Critical patent/DE69912304T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69912304T 1998-11-23 1999-11-22 Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen Expired - Lifetime DE69912304T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19867798A 1998-11-23 1998-11-23
US198677 1998-11-23
PCT/EP1999/008987 WO2000030651A1 (en) 1998-11-23 1999-11-22 Use of staurosporine derivatives for treating ocular neovascular diseases

Publications (2)

Publication Number Publication Date
DE69912304D1 true DE69912304D1 (de) 2003-11-27
DE69912304T2 DE69912304T2 (de) 2004-07-22

Family

ID=22734344

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69912304T Expired - Lifetime DE69912304T2 (de) 1998-11-23 1999-11-22 Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen

Country Status (19)

Country Link
EP (1) EP1131073B1 (de)
JP (2) JP2002530342A (de)
KR (1) KR100698449B1 (de)
CN (1) CN1172673C (de)
AT (1) ATE252387T1 (de)
AU (1) AU761092B2 (de)
BR (1) BR9915569A (de)
CA (1) CA2348890C (de)
DE (1) DE69912304T2 (de)
DK (1) DK1131073T3 (de)
ES (1) ES2211197T3 (de)
HK (1) HK1040182A1 (de)
ID (1) ID29970A (de)
IL (2) IL142757A0 (de)
NO (1) NO328085B1 (de)
NZ (1) NZ511559A (de)
PT (1) PT1131073E (de)
WO (1) WO2000030651A1 (de)
ZA (1) ZA200103925B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
CN1674868B (zh) * 2002-07-23 2010-09-29 诺瓦提斯公司 包含药物、软膏基质和增溶剂/分散剂的眼用软膏剂组合物
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
CN101580515B (zh) * 2008-05-16 2011-06-08 上海医药工业研究院 一种星形孢菌素提取纯化的方法
EP2406250B1 (de) 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Hemmer der akt-aktivität
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102924479A (zh) * 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法
EP2755482B1 (de) 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Kombination von mk-1775 und mk-8776 zur behandlung von krebs
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
JPH08502033A (ja) * 1992-07-08 1996-03-05 セルトリックス ファーマシューティカルズ，インコーポレイテッド ＴＧＦ−βを用いる眼疾患の治療方法
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
JP2002506028A (ja) * 1998-03-13 2002-02-26 ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 糖尿病性網膜症または眼炎症の処置におけるゲニステインのようなタンパク質チロシンインヒビターの使用

Also Published As

Publication number Publication date
CA2348890C (en) 2009-05-12
DE69912304T2 (de) 2004-07-22
ES2211197T3 (es) 2004-07-01
WO2000030651A1 (en) 2000-06-02
ID29970A (id) 2001-10-25
CN1328462A (zh) 2001-12-26
PT1131073E (pt) 2004-03-31
ATE252387T1 (de) 2003-11-15
ZA200103925B (en) 2002-07-25
AU1506600A (en) 2000-06-13
CA2348890A1 (en) 2000-06-02
KR100698449B1 (ko) 2007-03-23
AU761092B2 (en) 2003-05-29
BR9915569A (pt) 2001-08-14
CN1172673C (zh) 2004-10-27
NO328085B1 (no) 2009-11-30
EP1131073A1 (de) 2001-09-12
DK1131073T3 (da) 2004-02-02
NO20012490D0 (no) 2001-05-21
IL142757A0 (en) 2002-03-10
HK1040182A1 (en) 2002-05-31
NZ511559A (en) 2004-01-30
JP2002530342A (ja) 2002-09-17
JP2011088938A (ja) 2011-05-06
IL142757A (en) 2007-07-04
KR20010078398A (ko) 2001-08-20
NO20012490L (no) 2001-06-25
EP1131073B1 (de) 2003-10-22

Similar Documents

Publication Publication Date Title
DE60138137D1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
DE69713032D1 (de) Verwendung von SCF für Behandlung der Cornea
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
DE69834658D1 (de) Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE198044T1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
DE69305776D1 (de) Behandlung neurodegenerativer Krankheiten
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
ATE254461T1 (de) Behandlung von augenschmerzen
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE60045048D1 (de) Skleraprothese zur Behandlung der Weitsichtigkeit und anderer Augenkrankheiten
DE60130872D1 (de) Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
DE69930271T8 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
DE69912304D1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
DE69613386D1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
ATE278401T1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen
MY145266A (en) Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN